FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is a method for the suppression of physiological disorders related to abnormal angiogenesis, specified in retinopathy, diabetic retinopathy, macular degeneration, retinopathy of prematurity, age-related macular degeneration, pancreatic tumour and glioma, involving the administration of an effective amount of 3-[(5-(2,3-dimethoxy-6-methyl-1,4-benzoquinolinyl)]-2-nonyl-2-propenoic acid (E3330) or its pharmaceutically acceptable salts or solvates. The decreased EHF-1α, NFKβ, AP-1 activity by E3330 and the suppression thereby of the growth, survival. Migration and metastasis of tumour cells are accompanied by the absence of the major suppression of the growth of normal cells (hemopoietic embyo cells or CD34+ human progenitors). Besides, E3330 has enhanced the therapeutic effect of other cytotoxic preparations.
EFFECT: reducing the amount of VGEF and proliferation of retinal endothelial cells by E333O even in the presence of a fibroblast growth factor, both in the normal oxygen conditions, and in the hypoxia by the inhibition of the oxidation-reduction activity of Apel/Ref-1.
12 cl, 35 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| POTENTIATION OF CYTOTOXICITY CAUSED BY ANTI-CD38-IMMUNE TOXIN | 2000 |
|
RU2261090C2 |
| COMPOUNDS AND METHODS FOR TREATING LEUKEMIA | 2013 |
|
RU2672553C2 |
| SYSTEMS, METHODS AND COMPOSITIONS FOR CANCER TREATMENT | 2012 |
|
RU2644635C2 |
| TREATING CANCER WITH COMBINATION OF RADIATION THERAPY, CERIUM OXIDE NANOPARTICLES AND CHEMOTHERAPEUTIC AGENT | 2015 |
|
RU2704811C2 |
| CONJUGATE POSSESSING SELECTIVE EFFECT WITH RESPECT TO CANCER TUMORS | 2005 |
|
RU2303997C2 |
| METHOD OF USING 4-((5,10-DIMETHYL-6-OXO-6,10-DIHYDRO-5H-PYRIMIDO[5,4-b]THIENO[3,2-e][1,4]DIAZEPIN-2-YL)AMINO)BENZENESULFONAMIDE (XMU-MP-1) TO INHIBIT GROWTH OF BURKITT'S LYMPHOMA CELLS | 2023 |
|
RU2814013C1 |
| STERINE DERIVATIVES AND SYNTHESIS AND USE THEREOF | 2010 |
|
RU2507211C2 |
| TREATMENT OF CANCER BY PARVOVIRUS IN COMBINATION WITH BEVACIZUMAB | 2016 |
|
RU2679442C1 |
| FUSED PROTEIN WITH EFFECT OF ANGIOGENESIS INHIBITOR | 2008 |
|
RU2372354C1 |
| MONOCLONAL ANTIBODIES FOR TUMOUR TREATMENT | 2009 |
|
RU2531758C2 |
